#3876 JARID1A (D28B10) Rabbit mAb
|
CSTコード | 包装 | 希望納入価格 (円) |
||
---|---|---|---|---|
#3876S | 100 μL | 56,000 | ログインすると国内在庫状況がご確認いただけます。
| |
#3876T | 20 μL | 39,000![]() Custom Antibody Sampler Kitの構成品を選択できます。 5本以上を選択し、ページ右上のCartから製品確定書を発行してください。 尚、構成品の単品販売は致しておりません。 |
感度 | 分子量 (kDa) | 抗体の由来 | 貯法 | |
---|---|---|---|---|
内在性 | 200 | Rabbit IgG | -20℃ |
種交差性 (社内試験済) | |
---|---|
ヒト、マウス | ラット、ウシ |
ウェスタンブロッティング (1:1000)、免疫沈降 (1:100)
特異性・感度 | |
---|---|
内在性レベルのJARID1A タンパク質 (両アイソフォーム) を検出します。JARID1B、JARID1C、JARID1D を含む他のJARID タンパク質とは交差しません。 |
使用抗原 | |
---|---|
ヒトのJARID1A タンパク質 (合成ペプチド) |
ホモロジー (相同性) 検索をご希望の場合 >>>
ホモロジー検索をご要望の際は、ご希望のサンプル種のアミノ酸配列とともにお問合せください。
社内データ |
---|
※下記の社内データは、すべて3876 の推奨プロトコールで実験した結果です。
バックグラウンド |
---|
The methylation state of lysine residues in histone proteins is a major determinant for formation of active and inactive regions of the genome and is crucial for proper programming of the genome during development (1,2). Jumonji C (JmjC) domain-containing proteins represent the largest class of potential histone demethylase proteins (3). The JmjC domain can catalyze the demethylation of mono-, di-, and tri-methyl lysine residues via an oxidative reaction that requires iron and α-ketoglutarate (3). Based on homology, both humans and mice contain at least 30 such proteins, which can be divided into 7 separate families (3). The JARID (Jumonji/AT-rich interactive domain-containing protein) family contains four members: JARID1A (also RBP2 and RBBP2), JARID1B (also PLU-1), JARID1C (also SMCX) and JARID1D (also SMCY) (4). In addition to the JmJC domain, these proteins contain JmJN, BRIGHT, C5HC2 zinc-finger, and PHD domains, the latter of which binds to methylated histone H3 (Lys9) (4). All four JARID proteins demethylate di- and tri-methyl histone H3 Lys4; JARID1B also demethylates mono-methyl histone H3 Lys4 (5-7). JARID1A is a critical RB-interacting protein and is required for Polycomb-Repressive Complex 2 (PRC2)-mediated transcriptional repression during ES cell differentiation (8). A JARID1A-NUP98 gene fusion is associated with myeloid leukemia (9). JARID1B, which interacts with many proteins including c-Myc and HDAC4, may play a role in cell fate decisions by blocking terminal differentiation (10-12). JARID1B is over-expressed in many breast cancers and may act by repressing multiple tumor suppressor genes including BRCA1 and HOXA5 (13,14). JARID1C has been found in a complex with HDAC1, HDAC2, G9a and REST, which binds to and represses REST target genes in non-neuronal cells (7). JARID1C mutations are associated with X-linked mental retardation and epilepsy (15,16). JARID1D is largely uncharacterized.
- Kubicek, S. et al. (2006) Ernst Schering Res Found Workshop , 1-27.
- Lin, W. and Dent, S.Y. (2006) Curr Opin Genet Dev 16, 137-42.
- Klose, R.J. et al. (2006) Nat Rev Genet 7, 715-27.
- Benevolenskaya, E.V. (2007) Biochem Cell Biol 85, 435-43.
- Christensen, J. et al. (2007) Cell 128, 1063-76.
- Yamane, K. et al. (2007) Mol Cell 25, 801-12.
- Tahiliani, M. et al. (2007) Nature 447, 601-5.
- Pasini, D. et al. (2008) Genes Dev 22, 1345-55.
- van Zutven, L.J. et al. (2006) Genes Chromosomes Cancer 45, 437-46.
- Secombe, J. et al. (2007) Genes Dev 21, 537-51.
- Barrett, A. et al. (2007) Int J Cancer 121, 265-75.
- Dey, B.K. et al. (2008) Mol Cell Biol 28, 5312-27.
- Barrett, A. et al. (2002) Int J Cancer 101, 581-8.
- Lu, P.J. et al. (1999) J Biol Chem 274, 15633-45.
- Tzschach, A. et al. (2006) Hum Mutat 27, 389.
- Jensen, L.R. et al. (2005) Am J Hum Genet 76, 227-36.
使用例 |
---|
Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
本製品は試験研究用です。